Donor Bone Marrow Offered to Patients With Blood Cancers or Blood Disorders
Offers donor bone marrow transplant to people with blood cancers or disorders.
Key facts
- Who runs it
- Ossium Health, Inc.
- Where
- Birmingham, Columbus, Detroit, Duarte, and Nashville, United StatesSee the 5 sites
- Trial code
- Registry title
- HPC Offered for PRESERVE Expansion
- Status
- Recruiting
- People taking part
- 10 people, planned
- Started
- 27 Jun 2024
- Expected to end
- Aug 2029
- Type of study
- Observational
- Treatments tested
- Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 to 80 whose doctor has decided they can have a donor bone marrow transplant for a blood cancer or blood disorder, and that the possible benefit outweighs the risks.
- Age
- 12 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Blood cancers or blood disorders for which the treating doctor has decided on a donor bone marrow transplant.
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients aged 12-80 may be eligible* to receive bone marrow for transplantation through the Ossium HOPE Program if:
- Their treating physician determined they are eligible for allogeneic bone marrow transplant Their treating physician determined that the potential benefit outweighs the potential risks
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 80 years old?
Where in United States
- University of Alabama BirminghamBirmingham, United StatesContact: Mary UnderwoodTaking people
- The Ohio State University Medical CenterColumbus, United StatesContact: Nicole SzuminskiTaking people
- Henry Ford HealthDetroit, United StatesContact: Kelly WallsTaking people
- City of HopeDuarte, United StatesContact: Lindsay PoehlmanTaking people
- TriStar Centennial Medical centerNashville, United StatesContact: Angela HeineTaking people
About the trial
What the trial wants to find out
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product
The group in the trial
- Ossium HPC, Marrow
Ossium HPC, Marrow will be provide for infusion on the day of transplant
Treatment: Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for HOPE Patients With Hematologic Malignancies or Disorders
- Plain-language title
- Donor Bone Marrow Offered to Patients With Blood Cancers or Blood DisordersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07145411, who can take part
- Record updated
- 6 November 2026